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GenotypesAbstract Background: Gaucher’s disease (GD) is an autosomal recessive genetic disorder that
results from pathogenic mutations of GBA gene encoding the enzyme glucocerebrosidase (acid
b-glucosidase). Of the approximately 300 mutations associated with GD, 4 accounts for the major-
ity of mutations seen in GD patients: N370S, L444P, 84 GG and IVS2+1.
Aim: Establishing and providing, clinical and molecular backgrounds of pediatric patients with
GD in Upper Egypt.
Subjects and methods: The present study is a cross sectional study, carried out on 26 pediatric
patients with GD. They were recruited from the pediatric outpatient clinics and inpatients Pediatric
departments of Assiut and Qena University hospitals, Upper Egypt. Clinical evaluation and muta-
tion analysis using commercially available strip assay kit after PCR amplification of the target gene
were done for all included GD patients.
Results: Consanguinity between patients’ parents was present in 73.1% of the included patients.
76.9% of included patients were of type 1 GD, while 23.1% were of type 3 GD and none of our
patients was classified as type 2 GD. The main frequent clinical presentations of GD in this study
were hepatosplenomegaly (88.5%); pallor (76.9%); abdominal distension (61.5%) and muscu-
loskeletal involvement (37.1%). Neurological abnormalities of type 3 GD included in this study
were squint, seizures and delayed mental development. Five different genotypes were detected,
homozygous for the mutation L444P, homozygous for the mutation N370S, heterozygous for theed Hum
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Genet (2016), http://dx.doi.org/10.1016/j.ejmmutations N370S and rec Ncil, heterozygous for IVS2 +1 and rec NciI, heterozygous for L444P
and IVS2 +1.
Conclusions: Non-neuropathic type 1 and type 3 GD were the only clinical types found in the
present study. The most common mutant alleles found in this study were L444P and N370S.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gaucher’s disease (GD) is one of the most common lysosomal
storage diseases and one of the rare genetic diseases for which
therapy is now available. GD is an autosomal recessive genetic
disorder that results from pathogenic mutations of GBA gene
encoding the enzyme glucocerebrosidase (acid b-glucosidase),
which located on 1.q21.31. The absence or low activity of this
enzyme leads to a progressive accumulation of its substrate
(glucosylceramide ‘‘GlcCer”) into macrophages [1]. These cells
are natural phagocytes that are involved in the degradation of
the membrane glycolipids from red blood cells (RBCs) and
leukocytes. GlcCer-laden macrophages are not killed by the
accumulation of the substrate, but tend to transform into Gau-
cher cells [2]. Moreover, all cells of the mononuclear phagocyte
system, and especially tissue macrophages of the liver (Kupffer
cells), spleen, bone marrow (osteoclasts) can be affected in GD
[3]. Accumulation of glucosylceramide in these organs con-
tributes directly to massive hepatosplenomegaly and pancy-
topenia [4].
Progressive infiltration of Gaucher cells into the bone and
bone marrow may lead to thinning of the cortex, pathologic
fractures, bone pain and joint collapse. In about one third of
patients, this infiltration leads to avascular necrosis of the
bone, which can eventually result in irreversible bone destruc-
tion [5].
The phenotypes of GD are a continuum of degrees of
involvement, but can be divided categorically into three major
clinical types that are delineated by the absence (type 1) or
presence (types 2 and 3) of primary central nervous system
involvement [6]. The neuropathic involvement in types 2 and
3 GD results from accumulation of glucosylceramide and its
neurotoxic derivative, glucosyl sphingosine, with subsequent
neuronal loss via eliciting apoptotic signals [7].
Molecular analysis of the GBA gene is complex, as this
gene is linked with an actively transcribed, highly homologous
(96% identity) pseudogene (5 kb) that also harbors several
mutations, however only mutations in the active gene lead to
GD [8]. Of the approximately 300 mutations associated with
GD, 4 accounts for the majority of mutations seen in GD
patients: N370S, L444P, 84 GG and IVS2+1 [9].
Few studies could be traced in the literature regarding the
clinical and genetic assessment of pediatric patients with GD
in Egypt, especially in Upper Egypt, where a high rate of con-
sanguineous marriage allows a higher chance for appearance
of such autosomal recessive metabolic disorders, so the present
study aimed to identify the main presenting manifestations, the
most frequent clinical types and genotypes and correlating
them to each other among pediatric patients with GD in
Upper Egypt.Given the rarity of GD, we hope that this study
helps to build more experience in pediatric GD in Upper
Egypt.et al., Clinical and genetic assessment o
hg.2016.08.0052. Subjects and methods
2.1. Study design and setting
The present study is a cross sectional analytical study carried
out on 26 pediatric patients, 14 males and 12 females. They
were recruited from the pediatric outpatient clinics and inpa-
tients Pediatric departments of Assiut and Qena University
Hospital which are of the major tertiary referral pediatric hos-
pitals in Upper Egypt after approval of the university hospital
ethical committee. Prior to initiation of the study; every subject
and his/her parents were informed about the aim of the study
and gave a written consent. The study was carried out during
the period from May 2015 to May 2016. As this is an explora-
tory study, only percentage and proportions are reported.
2.2. Data collections
History taking for all included pediatric patients, including:
Personal history/Family History: age, sex, residence, history
of consanguineous marriage among the patients’ parents, his-
tory of abdominal distention, bone pain, fatigue, easy bruising,
delayed growth, muscle weakness, cognitive impairment, sei-
zures, dementia, heart and lung problems, history of blood
transfusions or splenectomy. Family history of fetal deaths
or miscarriages or genetically affected siblings with GD was
also included. Thorough clinical examination for: vital signs;
anthropometric measurements; abdominal examination (if
there is splenomegaly or hepatosplenomegaly); musculoskele-
tal examination (if there is bone tenderness or skeletal deformi-
ties); neurological examination (if there is spasticity,
opisthotonus ataxia, hypertonia, hyperreflexia); cardiac and
chest examination were done for all included patients.
Diagnosis of the included patients with GD was based upon
the following inclusion criteria [10]; clinically: unexplained iso-
lated splenomegaly or hepatosplenomegaly with skeletal
abnormalities (bone pain or spontaneous fractures) associated
with or without delayed physical and/or mental development
and/or neurologic abnormalities. Laboratory: anemia and/or
thrombocytopenia to be confirmed by the presence of reduced
leukocyte glucocerebrosidase enzyme activity, increased
plasma chitotriosidase activity with or without typical Gau-
cher cells infiltrate in the bone marrow aspirate examination
or liver biopsy.
2.3. Study methods
(A) Imaging tools (taken already from the file of the patients)
1. Abdominal ultrasound was done to determine liver and
spleen sizes.f pediatric patients with Gaucher’s disease in Upper Egypt, Egypt J Med Hum
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EEG, C.T brain for selected patients.
(B) Laboratory workup
Three cc of venous blood was drawn from the included chil-
dren on EDTA tubes, stored at 20 C till the time of muta-
tion analysis. Strip assay method was done using a
commercially available strip assay kit supplied by Vienna
Lab Diagnostics GmbH, Gaudenzdorfer Guertel 43-45, A-
1120 Vienna, Austria: The procedure included three steps:
(1) DNA isolation, (2) PCR amplification using biotinylated
primers (using VeriFlexTM 96-Well Thermal Cycler, Applied
Biosystems, USA), (3) hybridization of amplification products
to a test strip containing allele-specific oligonucleotide probes
immobilized as an array of parallel lines. Bound biotinylated
sequences were detected using streptavidin-alkaline phos-
phatase and color substrates. The assay covered 8 common
GBA mutations: 84GG [452 +G], IVS2+1 [484 G> A],
N370S [1226 A > G], V394L [1297 G > T], D409H [1342
G > C], L444P [1448 T > C], R463C [1504 C > T], R496H
[1604 G > A], as well as 2 recombinant alleles derived from
crossover between the GBA functional gene and pseudogene
(rec NciI, rec TL). The genotype of a sample was determined
using the enclosed Collector TM sheet. The processed Test
strips were placed into one of the designated fields aligned it
to the schematic drawing using the red marker line (top) and
the green marker line (bottom) then it was fixed with adhesive
tape. The positive reaction of the uppermost Control line
ensured the correct function of Conjugate Solution and Color
Developer. Probes 1 to 8 (mutant) and 10 to 17 (wild type)
refer to the respective alleles as present on the GBA functional
gene. Rec reporter probes 9 and 18 indicate whether a recom-
bination event has occurred due to crossover between the
functional gene and the GBA pseudogene in the region of
exons 9–10 (flanked by mutations V394L and L444P). The fol-
lowing recombinant alleles have been documented: rec TL:
crossover point located between V394L and D409H and rec
NciI: crossover point located between D409H and L444P. A
positive signal for the mutant rec reporter probe indicates
the presence of one of these rec alleles, the wild type rec repor-
ter probe reads positive for GBA alleles without crossover in
this region. In case of a positive mutant rec reporter probe,
rec TL and rec NciI can be distinguished by the presence or
absence of positive staining for mutant D409H.
3. Results
The present study included 29 GD pediatric patients, 14 males
(53.8%) and 12 females (46.2%). The mean age of the studied
patients was 8.68 ± 5.34 years with age range from 0.17 to
17 years. The males to females ratio was 1.2:1. The mean age
at presentation was 3.06 ± 4.22 years with age range from
0.08 to 17 years. Most of patients were from Assiut gover-
norate (65.4%) followed by Sohag governorate (19.2%) then
Minia (7.7%) and the least number were from Qena gover-
norate (3.8%) and Aswan governorate (3.8%). Most of
patients were rural residents (92.3%) and the remaining were
urban residents (7.7%). Consanguinity between patients’ par-
ents was present in 19 patients (73.1%). In addition, fourteen
children (53.8%) had at least one affected sibling and two
patients (7.7%) had history of sibling death in early childhoodPlease cite this article in press as: Saleem TH et al., Clinical and genetic assessment o
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.005most probably due to GD. 76.9% of included patients were of
type 1 GD, while 23.1% were of type 3 GD and none of our
patients was classified as type 2 GD.
The frequency distribution of the main clinical and imaging
findings of the studied patients at time of diagnosis are listed in
Table 1, hepatosplenomegaly was present in 88.5% of cases,
pallor (76.9%), and abdominal distension (61.5%). Muscu-
loskeletal involvement was present in 73.1% in form of chronic
bone pain (38.5%), bone crises (3.8%), bone fractures
(19.2%), restricted mobility (7.7%) and/ or radiological bone
involvement (57.7%). The major radiological bone involve-
ment in this study were Erlenmeyer Flask Deformity
(53.8%), kyphoscoliosis (11.5%), pectus carinatum (15.4%)
and avascular necrosis of femoral head (3.8%). 30.8% of the
studied cases complained from recurrent chest infections and
23.1% had bleeding tendency in the form of epistaxis, easy
bruising, menorrhagia or prolonged bleeding after superficial
wounds.
Among the 52 alleles studied, 38.5% contained the L444P
mutation, 23.1% were shown to have the N370S mutation
and 9.6% contained the IVS2+1 mutation. The recombinant
allele recNcil was identified in 13.4%, Table 2. Five different
genotypes were detected in the studied patients; homozygous
for the mutation L444P (30.8%), homozygous for the muta-
tion N370S (15.4%), heterozygous for the mutations N370S
and rec Ncil (15.4%), heterozygous for IVS2 +1 and rec NciI
(11.5%), heterozygous for IVS2 +1 and L444P (7.7%),
heterozygous for L444P and second alleles were not detected
but occurred in 7.7%, while, in 11.5% it was not possible to
identify any of the alleles. Table 3 and Fig. 1.
4. Discussion
Regarding the demographic data of the pediatric patients with
Gaucher disease involved in this study; males to females ratio
was 1.2:1, which indicates that the inheritance of GD is not
linked to the sex chromosomes and reflects the autosomal
recessive nature of such metabolic disorders that affect males
and females in an equal proportion. Most of patients were
rural residents and few of them were urban residents. In agree-
ment with this finding, Giraldo et al. [11] and Tantawy et al.
[12], both reported no sex differences between patients having
Gaucher disease involved in their studies. Shawky et al. [13]
reported that the overall frequency of consanguinity in Egypt
is high and varies by region as it was higher in rural areas than
in semi-urban and urban areas and attributed this to the fact
that many Egyptian families in the rural communities prefer
marriage to the first cousins to preserve family structure, links
and provide social, economic and cultural benefits. This could
explain why most of the GD patients involved in the present
study were of rural residents. Consanguinity between patients’
parents in this study was present in 73.1% of patients. In
agreement with our findings, El-Beshlawy et al. [14], Khalifa
et al. [15] and Elgawhary et al. [16], all these studies reported
a higher rate of consanguineous marriage among the parents
of GD patients.
The international Collaborative Gaucher Group (ICGG)
Gaucher Registry revealed that non-neuropathic type 1 GD
is the most prevalent form worldwide [17]. Patients in the pre-
sent study were classified according to presence and nature of
neurological symptoms and signs, which were evaluated by af pediatric patients with Gaucher’s disease in Upper Egypt, Egypt J Med Hum
Table 1 Frequency distribution of the main clinical and imaging findings of the studied patients according to their clinical types at
time of diagnosis.
Variables* GD type I (n= 20) GD type III (n= 6) Total (n= 26)
No. % No. % No. %
Developmental delay
Physical delay 1 5.0 3 50.0 4 15.4
Physical and mental delay 0 0.0 3 50.0 3 11.5
Abdominal distension 12 60.0 4 66.7 16 61.5
Bleeding tendency 5 25.0 1 16.7 6 23.1
Recurrent chest infection 5 25.0 3 50.0 8 30.8
Pallor 14 70.0 6 100 20 76.9
Hepatosplenomegaly** 17 85.0 6 100 23 88.5
Isolated Splenomegaly** 2 10 0 0.0 2 7.7
Neurological involvement 6 100 6 23.1
Squint – – 5 83.3 5 19.2
Seizures – – 3 50.0 3 11.5
Musculoskeletal involvement 13 65.0 6 100 19 73.1
Bone pain 8 40.0 2 33.3 10 38.5
Bone crises 1 5.0 0 0.0 1 3.8
Bone fracture 5 83.3 0 0.0 5 19.2
Restricted mobility 0 0.0 2 33.3 2 7.7
Radiological evidence of bone involvement*** 9 45.0 6 100 15 57.7
Blood transfusion 10 50.0 4 66.7 14 53.8
Splenectomy 1 5.0 0 0.0 1 3.8
Joint replacement 1 5.0 0 0.0 1 3.8
Joint replacement 1 5.0 0 0.0 1 3.8
* Many cases presented with more than one clinical finding.
** Organ volumes were obtained by means of magnetic resonance imaging (MRI), computed tomography (CT) or ultrasound.
*** Radiological bone findings in this study were Erlenmeyer Flask Deformity, kyphoscoliosis, pectuscarinatum and avascular necrosis of
femoral head.
Table 2 Frequency distribution of the mutant alleles among the studied patients according to their clinical types.
Mutant allele GD type I (n= 20) GD type III (n= 6) Total (n= 26)
No. % No. % No. %
L444P 8 20.0 12 100 20 38.5
N370S 12 30.0 0 0.0 12 23.1
Rec NciI 7 17.5 0 0.0 7 13.4
IVS2 + 1 5 12.5 0 0.0 5 9.6
Unknown 8 20.0 0 0.0 8 15.4
Total number of mutant alleles 40 12 52
Table 3 Frequency distribution of the genotypes among the studied patients according to their clinical types.
Genotype GD type I (n= 20) GD type III (n= 6) Total (n= 26)
No. % No. % No. %
L444P/L444P 2 7.7 6 100 8 30.8
N370S/N370S 4 15.4 0 0.0 4 15.4
IVS2 + 1/L444P 2 7.7 0 0.0 2 7.7
N370S/rec NciI 4 15.4 0 0.0 4 15.4
IVS2 + 1/rec NciI 3 11.5 0 0.0 3 11.5
*?/L444P 2 7.7 0 0.0 2 7.7
*?/? 3 11.5 0 0.0 3 11.5
*? means that the allele couldn’t be identified.
4 T.H. Saleem et al.pediatric neurologist. Most of patients were of type 1 GD and
few of them were of type 3 GD, while, none of our patients was
classified as type 2 GD, however in this study, two childrenPlease cite this article in press as: Saleem TH et al., Clinical and genetic assessment o
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.005with homozygous L444P mutation (7.7%) exhibited type 1
phenotype and they need careful observation as they are at risk
for development of neuronopathic disease (type 3) in laterf pediatric patients with Gaucher’s disease in Upper Egypt, Egypt J Med Hum
Figure 1 Mutation analysis strip assay showing; (A) L444P/L444P mutation; (B) N370S/rec NciI compound heterozygous mutation; (C)
N370S/N370S mutation.
Characterization of pediatric patients with Gaucher’s disease 5childhood and should undergo regular evaluation for central
nervous system manifestations of GD. In agreement with these
findings, a study done by Stirnemann et al. [18] on GD patients
living in France concluded that type 1GD had the highest
frequency followed by types 2 and 3, both have the least fre-
quency. Also, a study done by El-Morsy et al. [8] on Egyptian
pediatric patients with GD found that about 2/3 of patients
have with type 1 GD and about 1/3 of patients have type 3
GD with no type 2 GD in their study. On the contrary, a study
done by Khalifa et al. [15] on Egyptian patients with GD
revealed that type 3 GD has the highest frequency followed
by type1 while type2 has the lowest frequency. This could be
explained by the fact that N370S homozygotes often have mild
disease and may have existed undiagnosed in the catchment
area of the Khalifa study.
Regarding the main clinical characteristics of GD patients
involved in this study, hepatosplenomegaly, pallor and abdom-
inal distension were among the most frequent encountered
symptoms of GD, followed by musculoskeletal involvementPlease cite this article in press as: Saleem TH et al., Clinical and genetic assessment o
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.005in the form of chronic bone pain, bone crises, bone fractures,
restricted mobility and/or radiological bone disease in the form
of Erlenmeyer Flask deformity, kyphoscoliosis, pectus carina-
tum and avascular necrosis of femoral head. Recurrent chest
infections and bleeding tendency (in the form of epistaxis, easy
bruising, menorrhagia or prolonged bleeding after superficial
wounds), were among the presenting manifestations .Neuro-
logical abnormalities of type 3 GD included in this study were
squint, seizures and developmental delay with delayed both
physical and mental development. In agreement with these
findings what was found in a study done by El-Morsy et al.
[8] on Egyptian pediatric patients with type1 and type3 GD.
In the present study, five different genotypes were detected
among GD patients, homozygous for the mutation (L444P)
has the highest frequency which was the only encountered
mutation in all pediatric patients with the neuronopathic type
3 GD, followed by homozygous for the mutation (N370S) and
heterozygous for the mutations (N370S and rec Ncil), which
were the most frequent genotypes in type 1 GD, then,f pediatric patients with Gaucher’s disease in Upper Egypt, Egypt J Med Hum
6 T.H. Saleem et al.heterozygous for the mutations (IVS2 +1 and rec NciI), while
the least frequent mutations were heterozygous for (L444P and
IVS2 +1).
In agreement with these findings: a study done by Elmonem
et al. [19] on Egyptian pediatric patients with GD found that
the most frequent genotype in these patients were homozygous
for the mutation L444P, with lower frequency of N370S
homozygous and N370S and IVS2+1 heterozygous and few
of these patients were heterozygous for L444P and second alle-
les were not detected or non-mutant alleles were discovered.
Another study done by El-Beshlawy et al. [14] on Egyptian
children with GD revealed that the most frequent genotype
of these patients were homozygous for the mutation L444P,
with lower frequency of D409H homozygous mutation, com-
pound heterozygous for L444Pand D409H, R359Q homozy-
gous and compound heterozygous for N370S and rec allele.
Another study done by Khalifa et al. [15] showed that
N370S/N370S was the most frequent genotype in type 1 GD
patients, while, all of type 3 GD patients tested in their study
were homozygous for the L444P mutation. Also another study
done by Koprivica et al. [20] demonstrated that homozygosity
for mutation L444P was present in large percent of patients
with type 3 GD in their study. Another study done by Stein
et al. [21] on patients with GD1 found that the most common
genotype was N370S/N370S. Also, a study done by Giraldo
et al. [22] on patients with GD in the Iberian Peninsula,
N370S/L444P was the most frequent genotype in type 1 GD
patients, followed by N370S/N370S, while the most frequent
genotype in type 3 GD were L444P/L444P and D409H/
D409H.
Regarding the association between genotype, age at diagno-
sis and clinical manifestations in the present study, the mean
age at diagnosis was older than 5 years for the patients with
N370S/N370S; while mean age at diagnosis was younger than
5 years for the remaining genotypes. Hepatosplenomegaly was
present in all patients with L444P/L444P, IVS2+1/L444P and
N370S/rec NciI genotypes, in 75% of patients with N370S/
N370S and in 33.3% of patients with IVS2+1/rec NciI
Musculoskeletal manifestations in the form of clinical and/or
radiological bone involvement were present in all patients with
at least one N370S allele and in 87.5% of patients homozygous
for L444P. On the contrary, a study done by El-Morsy et al. [8]
concluded that no significant association between GBA alleles
or genotype frequencies and different phenotypes of GD in
their study.5. Conclusion
Non-neuronopathic type 1 and type 3 GD were the only clin-
ical types found in the present study with homozygous N370S
and N370S/ rec NciI mutations were the most frequent geno-
types in type 1 GD patients, while homozygous L444P muta-
tion was the only encountered genotype in patients with type
3 GD.
Recommendations
Additional more comprehensive large-scale studies to strongly
correlate genotype and phenotype among pediatric patients
with GD in Upper Egypt are recommended.Please cite this article in press as: Saleem TH et al., Clinical and genetic assessment o
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